The LAIP in AML is a patient-specific phenotype that can be characterized based on one or more of the following features: (1) asynchronous antigenic expression of immaturity/maturity biomarkers, such as CD34/CD117 with CD15 or CD11b; (2) aberrant lineage antigen expression, such as the lymphoid antigens CD19, CD7, CD4, CD25, CD2, and CD56; (3) and overexpression, reduced expression, or loss of antigens (CD123, CD33, CD13, HLA-DR) [11,12]. This evidence concerns the gene CD34 and acute myeloid leukemia.